Related Experiment Video
Updated: Aug 9, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
[Converting enzyme inhibitors and coronary failure]
A Castaigne1, J P Saal, C Albo
1Service de cardiologie, hôpital Henri-Mondor, Créteil.
La Revue Du Praticien
|December 15, 1992
Summary
Angiotensin-converting enzyme (ACE) inhibitors help patients survive myocardial infarction by reducing left ventricular remodeling. However, their use in the acute phase requires careful consideration due to potential risks.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- Myocardial infarction (MI) leads to left ventricular dilatation and remodeling.
- Left ventricular remodeling, while aiding survival, increases ventricular workload.
- Early interventions like reperfusion and ACE inhibitors can mitigate these changes.
Purpose:
- To review the effects of ACE inhibitors on left ventricular remodeling post-myocardial infarction.
- To analyze the established and potential indications of ACE inhibitors in coronary heart disease patients.
- To reconcile conflicting data regarding ACE inhibitor use in the acute phase of MI.
Summary:
- ACE inhibitors have demonstrated benefits in reducing left ventricular dilatation and remodeling following myocardial infarction.
- In patients with heart failure or left ventricular dysfunction post-MI, ACE inhibitors improve survival and reduce adverse events.
- While beneficial in experimental models, ACE inhibitor administration during acute MI in humans showed increased mortality in one large trial, necessitating careful evaluation of current indications.
Impact:
- Provides a comprehensive overview of ACE inhibitor efficacy in managing post-myocardial infarction complications.
- Helps clinicians determine appropriate use of ACE inhibitors in patients with coronary heart disease.
- Highlights the importance of risk-benefit assessment for ACE inhibitors, particularly in the acute phase of myocardial infarction.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...